• Home
  • About Modra
    • Overview
    • Management Team
    • Supervisory Board
  • Technology
    • Oral Taxane Therapy
    • Patient Benefit
    • Publications
  • Pipeline
    • Overview
    • ModraDoc006/r
    • ModraPac005/r
    • Partnerships
  • Careers
  • News
    • News & Events
    • Press Releases
  • Contact
Dizy-Logo

  • Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

    16 March, 2023

  • Modra Pharmaceuticals Presents In-Depth Data Analysis from Lower Dose Cohort in Phase 2b Study of Oral Taxane ModraDoc006/r in mCRPC Patients at 2022 ASCO Annual Meeting

    27 May, 2022

  • Modra Pharmaceuticals to Present New Phase 2b Data at the 2022 ASCO General Annual Meeting on ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer

    23 May, 2022

Follow Us

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 February 2021

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic

Article published in ASCO Daily News, February 10 2021

Previous Post Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
Next Post Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Contact
Modra Pharmaceuticals B.V.
Barbara Strozzilaan 201
1083 HN Amsterdam
The Netherlands
Phone: +31 (0)20-205 0188
E-mail: info@modrapharmaceuticals.com
Info
  • Imprint
  • Privacy Policy